Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma
- PMID: 19201517
- DOI: 10.1016/j.ejogrb.2008.12.014
Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma
Abstract
Objective: The aims of this study were to determine the prognostic factors, survival outcomes and response to adjuvant therapy in women with uterine carcinosarcoma treated in a single institution.
Study design: This is a cohort study of women diagnosed with carcinosarcoma and treated at the Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK. The medical records of all patients diagnosed with carcinosarcoma between January 1960 and July 2002 were reviewed.
Results: A total of 93 women were identified during this period. The median age was 67 years. The most common presentation was abnormal vaginal bleeding, occurring in 85%, followed by pelvic mass in 45%, and abdominal pain in 38%. At surgery there was extra-uterine spread in 54% of women. The median follow-up was 33 months (range 4-146 months). Adjuvant therapy was not associated with survival advantage. Recurrence was diagnosed in 55 patients (59%) and the overall 5-year survival for all stages was 33%. On multivariate analysis depth of myometrial invasion, stage and pelvic nodes metastasis were associated with poor survival.
Conclusion: The poor outcome for these patients may reflect the aggressive nature of carcinosarcoma and that at the time of presentation more than 50% have extra-uterine disease, which was associated with significant poorer survival. Systemic adjuvant therapy has not been associated with significant improvement in the outcome. More studies are needed to better define the appropriate treatment for this rare cancer.
Similar articles
-
Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.Gynecol Oncol. 2001 Oct;83(1):89-94. doi: 10.1006/gyno.2001.6334. Gynecol Oncol. 2001. PMID: 11585418
-
Prognostic factors and adjuvant therapy in uterine carcinosarcoma.Eur J Gynaecol Oncol. 2008;29(5):483-8. Eur J Gynaecol Oncol. 2008. PMID: 19051818
-
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.Gynecol Oncol. 2017 Apr;145(1):71-77. doi: 10.1016/j.ygyno.2017.01.010. Epub 2017 Mar 15. Gynecol Oncol. 2017. PMID: 28317560
-
An update on the management of uterine carcinosarcoma.Obstet Gynecol Surv. 2011 Nov;66(11):710-6. doi: 10.1097/OGX.0b013e31823e0c44. Obstet Gynecol Surv. 2011. PMID: 22186602 Review.
-
Rare uterine cancer: carcinosarcomas. Review from histology to treatment.Crit Rev Oncol Hematol. 2015 Apr;94(1):98-104. doi: 10.1016/j.critrevonc.2014.10.013. Epub 2014 Nov 7. Crit Rev Oncol Hematol. 2015. PMID: 25468677 Review.
Cited by
-
Clinical and imaging features of carcinosarcoma of the uterus and cervix.Insights Imaging. 2021 Oct 21;12(1):142. doi: 10.1186/s13244-021-01084-5. Insights Imaging. 2021. PMID: 34674042 Free PMC article.
-
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.Int J Clin Oncol. 2016 Feb;21(1):168-76. doi: 10.1007/s10147-015-0859-7. Epub 2015 Jun 18. Int J Clin Oncol. 2016. PMID: 26084780
-
Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.Int J Clin Oncol. 2018 Feb;23(1):114-120. doi: 10.1007/s10147-017-1181-3. Epub 2017 Aug 23. Int J Clin Oncol. 2018. PMID: 28836024
-
Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.Cancer Biol Ther. 2019;20(2):227-235. doi: 10.1080/15384047.2018.1523853. Epub 2018 Oct 25. Cancer Biol Ther. 2019. PMID: 30359167 Free PMC article.
-
Influence of Clinical and Surgical Factors on Uterine Carcinosarcoma Survival.Cancers (Basel). 2023 Feb 25;15(5):1463. doi: 10.3390/cancers15051463. Cancers (Basel). 2023. PMID: 36900255 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical